Humacyte Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	0	1.57	1.26	1.49	6.19
Revenue Growth (YoY)	-	23.91%	-15.29%	-75.90%	-
Gross Profit	0	1.57	1.26	1.49	6.19
Selling, General & Admin	23.5	22.88	21.13	12.01	16.28
Research & Development	76.55	63.26	61.34	54.08	75.6
Operating Expenses	100.05	86.14	82.47	66.09	91.88
Operating Income	-100.05	-84.58	-81.21	-64.6	-85.69
Interest Expense / Income	6.6	6.2	4.35	2.2	2.3
Other Expense / Income	4.13	-78.81	-59.08	-0.28	-2.57
Pretax Income	-110.78	-11.97	-26.48	-66.52	-85.42
Net Income	-110.78	-11.97	-26.48	-66.52	-85.42
Shares Outstanding (Basic)	103	103	40	6	20
Shares Outstanding (Diluted)	103	103	40	6	20
Shares Change	0.36%	157.82%	593.25%	-71.34%	-
EPS (Basic)	-1.07	-0.12	-0.66	-11.54	-4.25
EPS (Diluted)	-1.07	-0.12	-0.66	-11.54	-4.25
Free Cash Flow	-75.59	-72.18	-81.41	-55.84	-79.91
Free Cash Flow Per Share	-0.73	-0.70	-2.04	-9.68	-3.97
Gross Margin	-	100.00%	100.00%	100.00%	100.00%
Operating Margin	-	-5404.35%	-6429.77%	-4332.66%	-1385.02%
Profit Margin	-	-764.54%	-2096.36%	-4461.70%	-1380.67%
Free Cash Flow Margin	-	-4611.95%	-6445.76%	-3744.87%	-1291.61%
EBITDA	-96.41	2.49	-13.85	-55.89	-76.31
EBITDA Margin	-	159.11%	-1096.28%	-3748.49%	-1233.44%
Depreciation & Amortization	7.77	8.26	8.28	8.43	6.81
EBIT	-104.18	-5.77	-22.13	-64.32	-83.12
EBIT Margin	-	-368.37%	-1752.10%	-4314.02%	-1343.53%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).